Dr Deepak Kilari
Dr Deepak Kilari
Oncology
MD MS Haematology Medical Oncology (USA)
Registered Number – Milwaukee
Experience – 12 years
Language – English, Hindi, Telugu
Detailed Experience
Dr. Kilari practices at the Froedtert & the Medical College of Wisconsin Clinical Cancer Center where he specializes in the management of patients with genitourinary malignancies. Dr. Kilari moved back to the United States after finishing medical school in India to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center in New York. Subsequently he completed a fellowship in haematology and oncology at the University of Rochester, where he also served as a Chief Fellow. He received the ASCO foundation Merit award in 2013. His clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies.
Education & Training
Doctor Say -
Publications (52)
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.(Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC) JAMA Netw Open 2023 Sep 05;6(9):e2334208 PMID: 37721753 PMCID: PMC10507489 SCOPUS ID: 2-s2.0-85171513698 09/18/2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. (Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A) Res Sq2023 Aug 10 PMID: 37609284 PMCID: PMC10441451 08/23/2023
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. (Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D’Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH) Clin Genitourin Cancer 2023 Jul 19 PMID: 37558529 SCOPUS ID: 2-s2.0-85167777292 08/10/2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. (Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D’Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR) Oncologist 2023 Jun 27 PMID: 37368355 06/27/2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. (Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D’Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR) Oncologist 2023 Jun 27 PMID: 37368355 06/27/2023
Comprehensive genomic profiling: Does timing matter? (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B) Front Oncol 2023;13:1025367 PMID: 36865796 PMCID: PMC9971445 SCOPUS ID: 2-s2.0-85149381128 03/04/2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15023. (Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y) J Immunother Cancer 2023 Feb;11(2) PMID: 36822667 PMCID: PMC9950974 SCOPUS ID: 2-s2.085148679955 02/24/2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15023. (Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y) J Immunother Cancer 2023 Feb;11(2) PMID: 36822667 PMCID: PMC9950974 SCOPUS ID: 2-s2.085148679955 02/24/2023
Comprehensive genomic profiling: Does timing matter? (Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B) Frontiers in Oncology 2023;13 SCOPUS ID: 2-s2.0-85149381128 01/01/2023
Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. (Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D) Clin Genitourin Cancer 2021 Feb;19(1):87-91 PMID: 32778506 SCOPUS ID: 2-s2.0-85089247313 08/12/2020
Management of Acute Liver Dysfunction Due to Budd-Chiari Syndrome in the Setting of Tumor Thrombus and Advanced Renal Cell Carcinoma. (Stevens-Haas C, Maniar V, Dietrich P, Langenstroer P, Joyce L, White S, Kilari D, Hong J, Johnson S) Urology 2023 Mar;173:32-33 PMID: 36535364 SCOPUS ID: 2-s2.0-85146041736 12/20/2022
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. (Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR) Clin Genitourin Cancer 2023 Feb;21(1):55-62 PMID: 36411184 SCOPUS ID: 2-s2.0-85142487844 11/22/2022
Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. (Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L) Cancers (Basel) 2022 Sep 28;14(19) PMID: 36230636 PMCID: PMC9562906 SCOPUS ID: 2-s2.0-85139907579 10/15/2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. (Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV) Oncologist 2022 Oct 01;27(10):e783-e795 PMID: 36124924 PMCID: PMC9526483 SCOPUS ID: 2-s2.0-85139536391 09/21/2022
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. (Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT) Mol Cancer Ther 2020 Jan;19(1):231-246 PMID: 31548294 PMCID: PMC6946850 SCOPUS ID: 2-s2.0-85077669370 09/25/2019
Bystander LECT2 amyloidosis in tumor nephrectomy. (Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D’Souza A) CEN Case Rep 2023 Feb;12(1):104-109 PMID: 35986199 PMCID: PMC9892383 SCOPUS ID: 2-s2.0-85147317519 08/20/2022
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 PMID: 35179323 PMCID: PMC9844551 SCOPUS ID: 2-s2.0-85127335942 02/19/2022
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205 PMID: 34882781 SCOPUS ID: 2-s2.0-85120821529 12/10/2021
Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?(Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT) Cancers (Basel) 2021 Oct 17;13(20) PMID: 34680353 PMCID: PMC8533841 SCOPUS ID: 2-s2.0-85117018634 10/24/2021
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. (Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R) Prostate Cancer Prostatic Dis 2022 Sep;25(3):388-396 PMID: 34363009 PMCID: PMC9385488 SCOPUS ID: 2-s2.0-85112618674 08/08/2021
Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. (Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF) Pract Radiat Oncol 2021;11(6):527-533 PMID: 33848618 PMCID: PMC8638529 SCOPUS ID: 2s2.0-85107984420 04/14/2021
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. (Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA) Front Oncol 2020;10:581189 PMID: 33194712 PMCID: PMC7642690 SCOPUS ID: 2-s2.0-85095695510 11/17/2020
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort (Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA) Frontiers in Oncology 22 October 2020;10 SCOPUS ID: 2-s2.0-85095695510 10/22/2020
Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. (Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D) Clin Genitourin Cancer 2021 Feb;19(1):87-91 PMID: 32778506 SCOPUS ID: 2-s2.0-85089247313 08/12/2020
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precis Oncol2020;4:382-392 PMID: 32671317 PMCID: PMC7363399 07/17/2020
Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. (Kmak JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D) Case Rep Oncol 2020;13(1):456-461 PMID: 32399016 PMCID: PMC7204854 SCOPUS ID: 2-s2.0-85084410749 05/14/2020
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. (Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M) Prostate Cancer Prostatic Dis 2020 Dec;23(4):705-713 PMID: 32203070 PMCID: PMC7501185 SCOPUS ID: 2-s2.0-85082799475 03/24/2020
Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. (George G, Schmidt L, Tolat P, Riese M, Kilari D) J Immunother Cancer 2020 Feb;8(1) PMID: 32114501 PMCID: PMC7057424 SCOPUS ID: 2-s2.0-85080840435 03/03/2020
The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? (Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D) Clin Genitourin Cancer 2020 Aug;18(4):e478-e483 PMID: 32085986 SCOPUS ID: 2-s2.0-85079745146 02/23/2020
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. (Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT) Mol Cancer Ther 2020 Jan;19(1):231-246 PMID: 31548294 PMCID: PMC6946850 SCOPUS ID: 2-s2.0-85077669370 09/25/2019
Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. (Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA) J Natl Compr Canc Netw 2019 Jul 01;17(7):829-837 PMID: 31319388 SCOPUS ID: 2-s2.085070084884 07/19/2019
Palliative care education for oncologists: how are we doing? (Robbins JR, Kilari D, Johnston F) Ann Palliat Med2019 Sep;8(4):364-371 PMID: 30943741 SCOPUS ID: 2-s2.0-85073085975 04/05/2019
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. (Kilari D, D’Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P) Biol Blood Marrow Transplant 2019 Jun;25(6):1099-1106 PMID: 30794931 PMCID: PMC6559839 SCOPUS ID: 2-s2.0-85064954131 02/23/2019
CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade (Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A) JCO Precision Oncology2019;3:382-392 SCOPUS ID: 2-s2.0-85086473721 01/01/2019
Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. (Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L) Prostate Cancer Prostatic Dis 2018 Sep;21(3):411418 PMID: 29858592 PMCID: PMC6126974 SCOPUS ID: 2-s2.0-85047928806 06/03/2018
Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. (Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S) Case Rep Oncol 2017;10(3):897-909 PMID: 29279690 PMCID: PMC5731100 SCOPUS ID: 2-s2.0-85031826225 12/28/2017
Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. (Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L) Oncotarget 2017 Sep 08;8(38):6370363714 PMID: 28969022 PMCID: PMC5609954 SCOPUS ID: 2-s2.0-85028376284 10/04/2017
Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm.(Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D) Clin Genitourin Cancer 2017 Oct;15(5):e897-e901 PMID: 28645484 SCOPUS ID: 2-s2.085020921698 06/25/2017
Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. (Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT) Oncotarget 2017 Jan 10;8(2):3724-3745 PMID: 27741508 PMCID: PMC5356914 SCOPUS ID: 2-s2.0-85009775057 10/16/2016
Applications of Extracellular RNAs in Oncology. (Thompson JR, Zhu J, Kilari D, Wang L) Mol Diagn Ther 2017 Feb;21(1):1-11 PMID: 27688207 SCOPUS ID: 2-s2.0-84989170631 10/01/2016
Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. (Flynn T, Guancial EA, Kilari M, Kilari D) Clin Genitourin Cancer 2017 Feb;15(1):e95-e97 PMID: 27641657 SCOPUS ID: 2-s2.0-84994708562 09/20/2016
Gaps in nutritional research among older adults with cancer. (Presley CJ, Dotan E, Soto-Perez-deCelis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W) J Geriatr Oncol 2016 Jul;7(4):281-92 PMID: 27197919 PMCID: PMC4969118 SCOPUS ID: 2-s2.0-84971324913 05/21/2016
Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. (Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM) J Geriatr Oncol 2016 Jul;7(4):293-304 PMID: 27197916 PMCID: PMC4969104 SCOPUS ID: 2-s2.084971268860 05/21/2016
Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 PMID: 27187160 PMCID: PMC4871463 SCOPUS ID: 2s2.0-84969505076 05/18/2016
Role of copper transporters in platinum resistance. (Kilari D, Guancial E, Kim ES) World J Clin Oncol 2016 Feb 10;7(1):106-13 PMID: 26862494 PMCID: PMC4734932 SCOPUS ID: 2-s2.084956653652 02/11/2016
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. (Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH) Lung Cancer 2014 Jul;85(1):88-93 PMID: 24792335 PMCID: PMC4090351 SCOPUS ID: 2-s2.0-84901624214 05/06/2014
Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. (Kilari D, Venci N, Friedberg J, Bennett JM) Leuk Res Rep 2013;2(1):4-6 PMID: 24371766 PMCID: PMC3850386 SCOPUS ID: 2-s2.0-84878370734 12/29/2013
An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) J Mens Health 2012 Sep 01;9(3):182-189 PMID: 24416090 PMCID: PMC3886726 SCOPUS ID: 2s2.0-84865162164 09/01/2012
An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer (Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M) Journal of Men’s HealthSeptember 2012;9(3):182-189 SCOPUS ID: 2-s2.0-84865162164 09/01/2012
Management of cancer in the older adult. (Kilari D, Mohile SG) Clin Geriatr Med 2012 Feb;28(1):33-49 PMID: 22326034 SCOPUS ID: 2-s2.0-84856802493 02/14/2012
Management of cancer in the older adult. (Kilari D, Mohile SG) Clin Geriatr Med 2012 Feb;28(1):33-49 PMID: 22326034 SCOPUS ID: 2-s2.0-84856802493 02/14/2012
Inpatient management of sickle cell pain: a ‘snapshot’ of current practice. (Miller ST, Kim HY, Weiner D, Wager CG, Gallagher D, Styles L, Dampier CD, Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN)) Am J Hematol 2012 Mar;87(3):333-6 PMID: 22231150 PMCID: PMC5047515 SCOPUS ID: 2-s2.0-84862777383 01/11/2012
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. (Peters-Lawrence MH, Bell MC, Hsu LL, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith WR, Dampier CD, Minniti CP, Sickle Cell Disease Clinical Research Network (SCDCRN)) Contemp Clin Trials 2012 Mar;33(2):291-7 PMID: 22155024 PMCID: PMC3577351 SCOPUS ID: 2-s2.0-84856218422 12/14/2011
